Low Molecular Weight Heparin

• References

• 1 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
• 2 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
• 3 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574
• 4 Rosenberg RD. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Hemostasis and Thrombosis; Basic Principles and Clinical Practice, 3rd edition. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) JB Lippincott; Philadelphia: 1993. in press
• 5 Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Comm 1983; 116: 492-499
• 6 Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161-182
• 7 Maimone MM, Tollefsen DM. Activation of heparin cofactor II by heparin oligosaccharides. Biochem Biophys Res Commmun 1988; 152: 1056
• 8 Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostas 1992; 67 (06) 639-643
• 9 Barzu T, Molho P, Tobelem G, Petitou M, Caen JP. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Haematol 1984; 26: 243-247
• 10 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
• 11 Bara L, Samama MM. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1990; 556: 57-61
• 12 Harenberg J. Pharmacology of low molecular weight heparins. Sem Thromb Hemostas 1990; 16: 12
• 13 Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, Sie P. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Sem Thromb Hemostas 1988; 14: 18-27
• 14 Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107-112
• 15 Fernandez F, Nguyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-495
• 16 Carter CJ, Kelton JG, Hirsh J, Cerskus AL, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood 1982; 59: 1239-1245
• 17 Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG. A randomized double-blind trial of low molecular weight heparin in the initial treatment of proximal vein thrombosis. Thromb Haemostas 1991; 65 (Suppl) 872
• 18 Prandoni P. Fixed dose LMW heparin (CY216) as compared with adjusted dose intravenous heparin in the initial treatment of symptomatic proximal venous thrombosis. Thromb Haemostas 1991; 65 (Suppl) 872
• 19 Nurmohamed MT, Rosendaal FR, Buller HR. et al.: Low-molecular-weight heparin versus standard heparin in general and orthopedic surgery. Lancet 1992; 340: 152-156
• 20 Leyvraz PF, Bachmann F, Hoek J, Buller HR, Postel M, Samama M, Vandenbroek MD. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. Br Med J 1991; 303: 543-548
• 21 Anderson DR, O'Brien B, Levine MN, Hirsh J. Comparison of the cost-effectiveness of LMWH and standard heparin for the prevention of DVT following total hip arthroplasty (THR). Blood 1992; (Suppl. 80) (01) 318a
• 22 Melissari E, Das S, Kanthou C, Pemberton KD, Kakkar VV. The use of LMW heparin in treating thromboembolism during pregnancy and prevention of osteoporosis. Thromb Haemostas 1991; 65: 926 (abstr)